Abstract
Background
The aim of this study was to evaluate the efficacy and toxicities of second-line chemotherapy regimens with docetaxel and gemcitabine (GD), or paclitaxel and gemcitabine (GP) for advanced or metastatic urothelial carcinoma (UC) that did not respond to first-line platinum-based chemotherapy.
Methods
From 2002 to 2017, 78 patients with metastatic UCs that progressed after platinum-based chemotherapy were treated with either GD (n = 41) or GP (n = 37). We compared these two different regimens by analyzing their efficacy and toxicities in a retrospective manner.
Results
Of the 78 patients enrolled in this study, it was possible to determine treatment efficacy in 70; the proportion of patients with objective response and disease control were 8.6 (9/70) and 54.3% (38/70), respectively. The median progression-free survival and overall survival in the total population (GP and GD) were 3.5 (95% CI 0.6–53.3) and 9.6 months (95% CI 1.2–53.3), respectively. There was no significant difference between the two regimens (GD or GP) regarding survival outcomes. Treatment-related adverse events were mostly manageable, but one patient died as a result of febrile neutropenia. The presence of liver metastasis and anemia (Hb < 10.0 g/dl) was prognostic factors for worse survival.
Conclusions
Combination chemotherapy with either GP or GD was a favorable and well-tolerated second-line treatment regimen for patients with advanced or metastatic UC following the failure of a platinum-based regimen. Further study using a large prospective cohort is needed to identify patients who will benefit from second-line combination therapy.
Similar content being viewed by others
References
Logothetis CJ, Dexeus FH, Finn L et al. (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055. https://doi.org/10.1200/JCO.1990.8.6.1050
Saxman SB, Propert KJ, Einhorn LH et al. (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15(7):2564–2569. https://doi.org/10.1200/JCO.1997.15.7.2564
von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077. https://doi.org/10.1200/JCO.2000.18.17.3068
von der Maase H, Sengelov L, Roberts JT et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602–4608. https://doi.org/10.1200/JCO.2005.07.757
Ortmann CA, Mazhar D (2013) Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol 9(11):1637–1651. https://doi.org/10.2217/fon.13.139
Bellmunt J, de Wit R, Vaughn DJ et al. (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683
Dreicer R, Manola J, Schneider DJ et al. (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97(11):2743–2747. https://doi.org/10.1002/cncr.11413
Albers P, Park SI, Niegisch G et al. (2011) Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22(2):288–294. https://doi.org/10.1093/annonc/mdq398
Kobayashi K, Matsuyama H, Shimizu K et al. (2016) Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. Jpn J Clin Oncol 46(8):775–780. https://doi.org/10.1093/jjco/hyw071
Bellmunt J, Fougeray R, Rosenberg JE et al. (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24(6):1466–1472. https://doi.org/10.1093/annonc/mdt007
Sideris S, Aoun F, Zanaty M et al. (2016) Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol 4(6):1063–1067. https://doi.org/10.3892/mco.2016.821
Sonpavde G, Pond GR, Choueiri TK et al. (2016) Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol 69(4):634–641. https://doi.org/10.1016/j.eururo.2015.07.042
Raggi D, Miceli R, Sonpavde G et al. (2016) Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27(1):49–61. https://doi.org/10.1093/annonc/mdv509
Naiki T, Kawai N, Hashimoto Y et al. (2014) Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. Int J Clin Oncol 19(3):516–522. https://doi.org/10.1007/s10147-013-0574-1
Sonpavde G, Pond GR, Fougeray R et al. (2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63(4):717–723. https://doi.org/10.1016/j.eururo.2012.11.042
Bellmunt J, Choueiri TK, Fougeray R et al. (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855. https://doi.org/10.1200/JCO.2009.25.4599
Sternberg CN, Calabro F, Pizzocaro G et al. (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92(12):2993–2998
Meluch AA, Greco FA, Burris HA et al. (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19(12):3018–3024. https://doi.org/10.1200/JCO.2001.19.12.3018
Kaufman DS, Carducci MA, Kuzel TM et al. (2004) A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22(5):393–397. https://doi.org/10.1016/j.urolonc.2004.01.002
Li J, Juliar B, Yiannoutsos C et al. (2005) Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 23(6):1185–1191. https://doi.org/10.1200/JCO.2005.05.089
Fechner G, Siener R, Reimann M et al. (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60(1):27–31. https://doi.org/10.1111/j.1742-1241.2005.00663.x
McCaffrey JA, Hilton S, Mazumdar M et al. (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853–1857. https://doi.org/10.1200/JCO.1997.15.5.1853
Kim YS, Lee SI, Park SH et al. (2016) A phase II study of weekly docetaxel as second-line chemotherapy in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer 14(1):76–81. https://doi.org/10.1016/j.clgc.2015.09.008
Gitlitz BJ, Baker C, Chapman Y et al. (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98(9):1863–1869. https://doi.org/10.1002/cncr.11726
Kakutani S, Fukuhara H, Taguchi S et al. (2015) Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. Jpn J Clin Oncol 45(3):281–285. https://doi.org/10.1093/jjco/hyu201
Petrylak DP, de Wit R, Chi KN et al. (2017) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet 390(10109):2266–2277. https://doi.org/10.1016/S0140-6736(17)32365-6
Yuasa T, Urakami S, Yonese J (2018) Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol. https://doi.org/10.1007/s10147-018-1260-0
Suyama T, Ueda T, Fukasawa S et al. (2009) Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 39(4):244–250. https://doi.org/10.1093/jjco/hyp003
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Compliance with ethical standards
Conflict of interest
All authors declared that they have no conflict of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Takeyama, Y., Kato, M., Nishihara, C. et al. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. Int J Clin Oncol 23, 944–950 (2018). https://doi.org/10.1007/s10147-018-1288-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-018-1288-1